Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

abemaciclib

- PMLiVE

Eli Lilly unveils plans to invest $27bn in four new US manufacturing sites

The investment raises the company’s total US capital expansion commitments to more than $50bn since 2020

- PMLiVE

AstraZeneca’s camizestrant shows promise in phase 3 breast cancer study

More than two million cases of the disease were diagnosed globally in 2022

- PMLiVE

Eli Lilly and OliX partner to advance early-stage metabolic disease candidate

Metabolic-associated steatohepatitis is expected to affect over 19 million adults in the US by 2039

- PMLiVE

Eli Lilly shares two-year results for Omvoh in active Crohn’s disease patients

Inflammatory bowel disease affects almost one in every 100 people in the US

- PMLiVE

Novartis’ Kisqali granted MHRA approval to treat early breast cancer patients

The drug is already approved in the UK to treat advanced cases of the disease

- PMLiVE

UK government launches ‘landmark’ AI breast cancer screening trial

Approximately 55,000 cases of the disease are diagnosed every year in the UK

- PMLiVE

World Cancer Day – CoppaFeel! and NHS NELCA urge young people to ‘Check In’

The co-designed campaign aims to challenge misconceptions surrounding breast cancer

- PMLiVE

Roche shares positive overall survival results for Itovebi in advanced breast cancer

Approximately 56,800 new cases of breast cancer are diagnosed in the UK every year

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu granted FDA approval in breast cancer

More than 300,000 cases of breast cancer are diagnosed in the US every year

- PMLiVE

AstraZeneca/Daiichi Sankyo survey reveals breast cancer misconceptions in Europe

The questionnaire gathered insights from 7,750 adults across five countries

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Datroway granted FDA approval in breast cancer

More than 300,000 cases of breast cancer are diagnosed in the US every year

- PMLiVE

Eli Lilly’s Omvoh granted FDA approval to treat Crohn’s disease in adults

The drug is already approved in the US to treat ulcerative colitis, another form of inflammatory bowel disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links